Cite
HARVARD Citation
Rose, D. et al. (2017). Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic. Journal of medical economics. pp. 395-404. [Online].